相关实验视频

Updated: Feb 21, 2026

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model

Published on: June 4, 2017

成功的多模式治疗SMARCA4缺乏的鼻癌

Eisuke Ishigami¹, Masayoshi Kobayashi¹, Hiroyuki Morishita¹

¹Department of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine, Mie University, Tsu, Japan.

Ear, nose, & throat journal

|February 20, 2026

概括

缺少SMARCA4的鼻癌是一种罕见的癌症,预后不佳. 结合手术,放射治疗和化疗的多式治疗方法在治疗这种侵袭性瘤方面表现出有效性.

科学领域:

在瘤学瘤学.
病理学病理学病理学
手术瘤学手术瘤学

背景情况:

缺少SMARCA4的鼻癌是一种罕见的,具有不良预后的侵略性瘤实体.
这种情况的标准化治疗策略尚未建立.
准确的诊断可能具有挑战性,最初的活检有时会被误诊.

研究的目的:

报告一个SMARCA4缺陷鼻癌病例.
为了描述患有这种罕见瘤的患者的治疗和结果.
评估多模式治疗方法的有效性.

主要方法:

一名患有鼻瘤的47岁妇女接受了内镜内切除和前头骨基部重建.
在术后进行强度调节放射治疗 (IMRT).
用FP疗法 (5-甲和西斯) 进行辅助化疗,持续3个周期.

主要成果:

通过手术完成了彻底的瘤切除.
组织病理学检查在IMRT期间证实了SMARCA4缺陷癌症.
手术后2年1个月,患者仍然活着,没有任何疾病的迹象.

结论:

缺少SMARCA4的癌症是一种侵略性瘤,需要迅速和全面的管理.
综合手术,IMRT和化学疗法治疗不分化癌的多式疗法是一种潜在的有效策略.
需要进一步的研究来制定标准化的治疗指南.

关键词:

这就是SMARCA4的标志.在 SWI/SNF 中.内镜头骨底部手术术镜头骨基手术强度调节的辐射疗法.多模式疗法多模式疗法鼻腔未分化的癌瘤

更多相关视频

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Published on: February 28, 2019

Olfactory Neurons Obtained through Nasal Biopsy Combined with Laser-Capture Microdissection: A Potential Approach to Study Treatment Response in Mental Disorders

Olfactory Neurons Obtained through Nasal Biopsy Combined with Laser-Capture Microdissection: A Potential Approach to Study Treatment Response in Mental Disorders

Published on: December 4, 2014

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...